CAR.AU

40.36

+0.65%↑

WOR.AU

14.5

+4.17%↑

AZJ.AU

3.24

+0.62%↑

CAR.AU

40.36

+0.65%↑

WOR.AU

14.5

+4.17%↑

AZJ.AU

3.24

+0.62%↑

CAR.AU

40.36

+0.65%↑

WOR.AU

14.5

+4.17%↑

AZJ.AU

3.24

+0.62%↑

CAR.AU

40.36

+0.65%↑

WOR.AU

14.5

+4.17%↑

AZJ.AU

3.24

+0.62%↑

CAR.AU

40.36

+0.65%↑

WOR.AU

14.5

+4.17%↑

AZJ.AU

3.24

+0.62%↑

Search

CSL Ltd

Închisă

SectorSectorul industrial

214.15 -1

Rezumat

Modificarea prețului

24h

Curent

Minim

214.02

Maxim

216.32

Indicatori cheie

By Trading Economics

Venit

2B

Vânzări

-5.7B

2.5B

P/E

Medie Sector

22.772

38.44

EPS

4.13

Randament dividend

1.35

Marjă de profit

24.437

Angajați

29,904

EBITDA

-2.4B

858M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+31.72% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.35%

2.24%

Statistici piață

By TradingEconomics

Capitalizare de piață

-20B

105B

Deschiderea anterioară

215.15

Închiderea anterioară

214.15

Sentimentul știrilor

By Acuity

50%

50%

206 / 459 Clasament în Industrials

CSL Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 aug. 2025, 03:32 UTC

Principalele dinamici ale pieței

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 aug. 2025, 23:46 UTC

Câștiguri

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 aug. 2025, 22:15 UTC

Câștiguri

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 apr. 2025, 09:39 UTC

Principalele dinamici ale pieței

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 feb. 2025, 21:55 UTC

Câștiguri

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb. 2025, 21:34 UTC

Câștiguri

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18 aug. 2025, 23:46 UTC

Market Talk
Câștiguri

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 aug. 2025, 21:52 UTC

Câștiguri

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 aug. 2025, 21:51 UTC

Câștiguri

CSL to Cut Up to 15% of Staff>CSL.AU

18 aug. 2025, 21:49 UTC

Câștiguri

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 aug. 2025, 21:49 UTC

Câștiguri

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 aug. 2025, 21:48 UTC

Câștiguri

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 aug. 2025, 21:47 UTC

Câștiguri

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 aug. 2025, 21:46 UTC

Câștiguri

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 aug. 2025, 21:45 UTC

Câștiguri

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 aug. 2025, 21:45 UTC

Câștiguri

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 aug. 2025, 21:44 UTC

Câștiguri

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 aug. 2025, 21:43 UTC

Câștiguri

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 aug. 2025, 21:43 UTC

Câștiguri

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 aug. 2025, 21:42 UTC

Câștiguri

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 aug. 2025, 21:42 UTC

Câștiguri

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 iun. 2025, 02:15 UTC

Market Talk

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 apr. 2025, 07:01 UTC

Market Talk

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 mar. 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb. 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb. 2025, 21:40 UTC

Câștiguri

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb. 2025, 21:19 UTC

Câștiguri

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb. 2025, 21:13 UTC

Câștiguri

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb. 2025, 21:12 UTC

Câștiguri

CSL Interim Dividend US$1.30/Security

10 feb. 2025, 21:12 UTC

Câștiguri

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Comparație

Modificare preț

CSL Ltd Așteptări

Obiectiv de preț

By TipRanks

31.72% sus

Prognoză pe 12 luni

Medie 283.406 AUD  31.72%

Maxim 330 AUD

Minim 227.5 AUD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCSL Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

9

Cumpărare

4

Păstrare

0

Vânzare

Sentiment

By Acuity

206 / 459 Clasament în Sectorul industrial

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.